A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England

Ahmed Elsada; Amy Zalin-Miller; Craig Knott; Leonidas Caravotas

doi:10.1002/jha2.214

A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England

EJHaem. 2021 Jun 10;2(3):493-497. doi: 10.1002/jha2.214. eCollection 2021 Aug.

Authors

Ahmed Elsada¹, Amy Zalin-Miller^{2

3}, Craig Knott^{2

3}, Leonidas Caravotas¹

Affiliations

¹ Janssen UK High Wycombe UK.
² Health Data Insight CIC Cambridge UK.
³ National Disease Registration Service Public Health England London UK.

Abstract

Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage therapies they received using the national cancer registry for England and linked healthcare data. After a median follow-up time of 6.4 months from T ₀, median overall survival and time to next treatment were 8.2 and 5.3 months, respectively. This real-world data provide useful clinical insight into a little-studied patient population and highlight the poor outcomes in the UK setting.

Keywords: overall survival; real‐world data; relapsed or refractory multiple myeloma; salvage therapy; triple‐class exposed.